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Toxoplasma gondii (T. gondii) is an obligate intracellular para-
site that infects a wide range of hosts, including humans and 
domestic animals, throughout the world [1]. The infective 
forms of Toxoplasma initially invade the intestinal epithelium 
of the host, and then the parasite can lead to a congenital in-
fection during pregnancy and also can lead to severe morbidity 
and mortality in patients suffering from immunocompro-
mised conditions [2]. In veterinary industries, T. gondii infec-
tion is economically important since it can cause abortion and 
neonatal loss of sheep and goats [3]. Thus, the effective vaccine 
against Toxoplasma would be important for both humans and 
veterinary medical fields.
Mucosal vaccines, including nasal, oral, vaginal, and sublin-
gual ones, have been developed during the last decades [4]. 
Several oral and intranasal vaccines against cholera, polio, and 
influenza have been commercially available since 2003, and a 
commercial intranasal influenza vaccine for humans (Flu-
mist®) began to be used [5]. However, this vaccine was forbid-
den by Centers for Disease Control and Prevention (CDC) in 
USA after 2017 because of its inefficient protection against in-
fluenza among 2-17 year-old children [6]. Moreover, it could 
provoke narcolepsy and has been prohibited for use by the 
Korean Government.
Recently, eyedrop vaccines have been studied as an alterna-
tive mucosal vaccine, in various animal models, including 
fowls, bovines, mice, and ferrets, and proved to be effective for 
protecting hosts from pathogens [7,8]. Unlike intranasal vac-
cines, no ocularly inoculated materials enter the central ner-
vous system (CNS), and ocular vaccines have been reported to 
have no side effects on CNS [7,9]. However, there have been 
few studies evaluating the effects of eyedrop vaccines against T. 
gondii or other kinds of parasitic infections.
Recently, new vaccines using parasite-derived extracellular 
vesicles (EV), which contain exosomes and interact with host 
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Abstract: Immunogenicity of dendritic cell-derived exosomes stimulated with Toxoplasma gondii lysates (TLA exo), mixed 
with cholera toxin as an adjuvant, was investigated in mice immunized via 2 mucosal routes (ocular vs intranasal). BALB/c 
mice were injected 3 times with TLA exo vaccine at 2 week interval, and the levels of IgG in serum and IgA in tear, saliva, 
feces, and vaginal wash were measured. To observe the expression of T. gondii-specific B1 gene, mice infected with ME49 
T. gondii cysts were immunized with TLA exo or PBS exo (not stimulated with TLA), and their brain tissues were examined. 
The mice vaccinated via intranasal route elicited significantly higher humoral and mucosal immune responses compared 
with mice treated with PBS alone. Also, mice immunized via ocular route (by eyedrop) induced significantly higher T. gondii-
specific IgG in serum and IgA in tear and feces in comparison with PBS controls. B1 gene expression was significantly 
lower in TLA exo vaccinated mice than in PBS or PBS exo vaccinated mice. These results demonstrated that ocular immu-
nization of mice with TLA exo vaccine has the potential to stimulate systemic or local antibody responses. This study also 
highlighted an advantage of an eyedrop vaccine as an alternative for T. gondii intranasal vaccines.
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immunity, were reported [10-12]. In particular, dendritic cells 
(DCs) are known to secrete exosomes expressing functional 
MHC class I/II and T-cell costimulatory molecules on the sur-
face of EV [13]. The properties of these structures are compati-
ble for their use as an alternative vaccine to DC-based cell-free 
vaccines [13]. In the present study, we evaluated the immuno-
genicity of a Toxoplasma-DC-derived exosome vaccine inoculat-
ed via eye mucosa in comparison with an intranasal vaccine 
for inducing protective immunity against T. gondii in mice.
DC2.4 cells, a mouse DC line, were cultured in Dulbecco’s 
Modified Eagle’s Medium (DMEM, Welgene, Seoul, Korea) 
supplemented with 10% fetal bovine serum (FBS; Welgene), 4 
mM L-glutamine, 0.2 mM penicillin, and 0.05 mM streptomy-
cin (Welgene) at 37˚C in a 5% CO2 incubator. Toxoplasma lysate 
antigen (TLA) was prepared as previously described with slight 
modifications [14]. Parasites were resuspended in PBS (pH 7.4) 
and sonicated on ice. The supernatant, i.e., TLA, was filter-steril-
ized through a 0.22 µm membrane, and the protein concentra-
tion was determined using a NanoDrop 2000 spectrophotom-
eter (Thermo Scientific, Rockford, Illinois, USA). TLA was stored 
at -70˚C until required. T. gondii, ME49 strain, was maintained 
by injecting the cysts into the peritoneal cavity of BALB/c mice 
(Orient Bio Animal Center, Seongnam, Korea). The ME49 cysts 
in the brain of mice were harvested 3 months after the infec-
tion by mincing the brain tissue. To each experimental mouse, 
30 cysts were inoculated intraperitoneally.
Exosomes from DC2.4 cells, stimulated with TLA (TLA exo) 
or not (PBS exo), were isolated by differential ultracentrifuga-
tion following the protocol described by Aline et al. [2]. The 
concentration of isolated exosomes was determined by BCA 
protein assay kit (Pierce, Rockford, Illinois, USA) and Nano-
Drop 2000 spectrophotometer. To observe the morphological 
characteristics, exosomes isolated from DC2.4 cells were nega-
tively stained with 2% uranyl acetate for 1 min as previously de-
scribed [15]. They were observed using a JEOL 1200-EX II trans-
mission electron microscope (JEOL, Tokyo, Japan) equipped 
with an ES1000W Erlangshen CCD camera (Gatan, Pleasanton, 
California, USA) at an accelerating voltage of 80 kV. The exo-
somes were approximately 60-100 nm in size and cup-shaped 
(Fig. 1).
Specific pathogen-free BALB/c mice, aged 6-10 weeks, were 
purchased from Charles River Laboratories (Orient Bio, Sung-
nam, Korea). All mice were maintained in an experimental an-
imal facility under specific pathogen-free conditions at the De-
partment of Laboratory Animal Resources, Yonsei Biomedical 
Research Institute, Yonsei University (Seoul, Korea) and re-
ceived sterilized food (Certified Diet MF; Oriental Yeast, Osa-
ka, Japan) and filtered tap water. All animal experiments were 
approved by the Animal Research Committee of Yonsei Uni-
versity (IACUC 2015-0022, IBC 2014-034).
Prior to experimental manipulation, mice were anesthetized 
by intraperitoneal injection of ketamine (100 mg/kg) and xyla-
zine hydrochloride (10 mg/kg). For intranasal or ocular im-
munization, 1 μg of TLA or TLA exo Ags with 2 μg cholera tox-
in (CT) (List Biological Laboratories, Campbell, California, 
USA) per head was suspended in 10 μl PBS and dropped 3 
times at 2 week interval onto the surface of the cornea making 
a droplet or intranasally onto the nostrils using a micropipette. 
For eye drop inoculation, 5 μl was dropped per eye. To keep 
the vaccine solution as droplets on the eye and not overflown, 
the immunized mice were kept lying on mice’s abdomen in 
the cage until they wake up. At week 2 after the last immuniza-
tion, sera were obtained by retro-orbital bleeding. Tear wash 
samples were obtained by washing with 100 μl PBS per eye. 
Saliva was obtained following intraperitoneal injection of 
mice with pilocarpine (500 mg/kg; Sigma-Aldrich). Fecal sam-
ples were obtained by adding weighed feces to PBS containing 
0.1% sodium azide. The feces were mixed by vortexing and 
centrifugation, and the supernatants were collected for assay. 
Vaginal wash samples were collected by lavage with 100 μl 
Fig. 1. A dendritic cell-derived exosome isolated by differential ul-
tracentrifugation and negatively stained with 2% uranyl acetate. 
The observed exosome is shown as approximately 60-100 nm in 
size and cup-shaped in its structure under a transmission elec-
tron microscopy. A white arrow points an exosome.
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PBS. After the mice were sacrificed, nasal wash samples were 
obtained by flushing 100 μl PBS through the anterior (oral) 
entrance of the nasal passages using a pipette.
ELISA plates (Falcon, Franklin Lakes, New Jersey, USA) were 
coated with TLA (1 mg/ml) in PBS and were incubated over-
night at 4˚C. Blocking was done with 1% BSA (Sigma-Aldrich) 
in PBS. Horseradish peroxidase (HRP)-conjugated goat anti-
mouse IgG or IgA (Southern Biotechnology Associates, Birming-
ham, Alabama, USA) was added to each well and incubated 
overnight at 4˚C. For color development, tetramethylbenzidine 
solution (Moss, Pasadena, Maryland, USA) was used. Then, the 
plates were measured at 450 nm on an ELISA reader (Molecular 
Devices, Sunnyvale, California, USA) after addition of stopping 
solution (0.5 N HCl). Endpoint titers of antigen-specific anti-
bodies were expressed as reciprocal log2 titers of the last dilution 
that showed 0.1 absorbance over background levels.
Mice challenged with 30 ME49 cysts were observed for expres-
sion of T. gondii-specific gene (B1 gene) in the brain. At week 4 
after the challenge, mice were killed and their brains were re-
moved. Each brain was homogenized in 2 ml of PBS with a 
mortar and pestle. Total genomic DNA was isolated from each 
brain homogenate using DNeasy blood and tissue kit (Qiagen, 
Hilden, Germany). The expression levels of T. gondii specific B1 
gene were evaluated using real-time PCR. The Ct values were an-
alyzed using the comparative Ct (ΔΔCt) method. Normalization 
was performed by using the reference gene β-actin relative to the 
control. Data are expressed as the mean±SD, and statistical 
analyses were done by the t-test (Excel program).
At week 2 after the third vaccination of TLA or TLA stimulat-
ed DC exosomes (TLA exo), the levels of TLA-specific serum 
IgG and mucosal IgA derived from tear, saliva, feces, and vagi-
na were significantly increased in both eyedrop and intranasal 
vaccination groups (Fig. 2A). When TLA exo antigens derived 
from TLA-stimulated DCs were used, the increases of specific 
IgA antibody levels were higher in ED group than in IN group 
except in the saliva sample (Fig. 2B). However, TLA exo-specif-
ic serum IgG level was higher in IN group than in ED adminis-
tration group (Fig. 2B). Although TLA exo-specific serum IgG 
levels were significantly increased at week 6 post-immuniza-
tion in both ED and IN groups, IN vaccination did not induce 
significant increases of mucosal IgA except for the tear and fe-
ces samples (Fig. 2B). It was also shown that TLA exo protected 
BALB/c mice against intraperitoneal challenge with 30 ME49 
cysts of T. gondii. The mice vaccinated with TLA exo and infect-
ed with ME49 cysts had body weights similar to those of the 
non-vaccinated infected group (data not shown).
At week 6 post-inoculation, we evaluated the expression of B1 
gene as Toxoplasma-specific marker in the brain of TLA exo vacci-
nated mice (Fig. 3). The expression level of B1 gene was signifi-
cantly lower in TLA exo vaccinated group than in PBS or PBS exo 
vaccinated mice. These results strongly suggested that the eye-
drop TLA exo vaccination can help to reduce T. gondii specific 
gene in the brain of mice against acute T. gondii infection.
Our results demonstrated that the eyedrop administration 
of DC exosomes stimulated with TLA exhibited strong immu-
nogenicity inducing immune responses in mice through the 
Fig. 2. Toxoplasma gondii-specific antibodies (IgG and IgA) in serum and mucosal fluids of mice immunized through eyedrop (ED) or in-
tranasal (IN) administration with T. gondii lysate antigens (TLA) in cholera toxin as an adjuvant (A) or with TLA stimulated dendritic cell-de-
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production of T. gondii-specific antibodies and reduction of B1 
gene expression against infection with ME49 cysts. This is the 
first report of anti-Toxoplasma effects of DC-derived exosomes 
vaccinated via mucosal route, such as eyedrop or intranasal in-
oculation.
Although eyedrop vaccination of TLA exo in mice induced 
lower levels of antigen-specific serum IgG or mucosal IgA than 
those of TLA, the levels of TLA exo-specific antibodies were sig-
nificantly higher than those of PBS-treated controls. Mucosal 
samples from tear and feces in TLA exo treated mice showed 
significant increases of specific mucosal IgA and serum IgG 
levels. This may indicate that Toxoplasma antigens expressed or 
inserted on the exosomes derived from TLA-pulsed DCs was 
properly processed in DCs after the vaccine antigens were ad-
ministered by eyedrop, so that successful Toxoplasma-specific 
immunity could be induced. We demonstrated that TLA exo 
could induce protective immunity in mice against the acute 
stage of T. gondii infection. BALB/c mice challenged with a sub-
lethal dose of Toxoplasma cysts exhibited a dramatically lower 
expression of Toxoplasma B1 gene following parasite infection 
than that of untreated mice (PBS) or mice treated with exo-
somes derived from unpulsed DC2.4 cells (PBS exo). It is sur-
mised that the eyedrop TLA exo vaccine could activate antigen-
specific immune cells which lead to reduce the expression of 
B1 gene and inhibit the proliferation of Toxoplasma in the 
brain of infected mice.
The application scopes of EV, including exosomes and mi-
crovesicles (MV), is gradually expanding in the diagnostic and 
vaccination fields [16]. Especially, new approaches for vaccina-
tion were required to overcome the challenges for various in-
fectious diseases [16]. Candidates of exosome vaccines have 
been suggested for various viruses, including Ebola virus, in-
fluenza virus, Crimean-Congo hemorrhagic fever virus, West 
Nile virus, and hepatitis C virus, and parasites, such as Trichu-
ris, Leishmania, Schistosoma, and Toxoplasma [16-20].
Some groups evaluated the potential utility of DC-derived 
exosomes to mediate protective immunity against cutaneous 
leishmaniasis [18]. These findings suggested that the develop-
ment of a cell-free vaccine for immunoprophylaxis against 
leishmaniasis and other infectious diseases is feasible [18]. 
Another group reported that EV proteomic analysis showed 
numerous known vaccine candidates against schistosomes 
[19]. The analysis provided new avenues for the exploration of 
host-schistosome interactions and offered a potential mecha-
nism by which some vaccine antigens exert their protective ef-
ficacy [19]. EVs isolated from Trichuris muris also induced pro-
tective immunity in mice when administered as a vaccine 
without an adjuvant [20]. Several reports suggested innovative 
methods for discovery and development of new therapeutic 
strategies [21].
Normally, the contents of exosomes depend on the state 
(after external stimulation) of the stimulating cells [12]. In this 
study, we speculate that there may be specific antigens of Toxo-
plasma in exosomes derived from DCs stimulated with TLA 
through the production of T. gondii specific antibodies (Fig. 2). 
However, further studies are needed to explore the contents of 
exosomes derived from DCs stimulated with T. gondii through 
genomic and proteomic analyses.
The present study has a limitation in that it confirmed only 
the efficacy of eye-drop exosome vaccines rather than evaluat-
ing the safety of the vaccines. For developing safe vaccine can-
didates, we need to approach with various strategies, including 
use of alternative and safe adjuvants rather than CT. Further 
studies should be focused on new approaches using alterna-
tive adjuvant candidates for developing safe vaccines.
In conclusion, our results report a new approach of TLA-
stimulated DC-derived exosomes for vaccination against Toxo-
plasma infection. Further studies are needed to identify several 
antigens within exosomes which can be targeted by host anti-
bodies following vaccination. Although eyedrop vaccination 
needs to be evaluated for its further usefulness and limitations 
for clinical trials, it has the potential of an easy and alternative 
method for inducing protective immune responses against 
Toxoplasma infection.
Fig. 3. Expression levels of Toxoplasma gondii-specific B1 gene in 
the brain of mice inoculated with TLA-stimulated dendritic cell-de-
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